Portland-based Prelude Early Learning has received a $2 million Phase II grant from the NIH to expand its innovative music-to-literacy education programme, aiming to enhance pre-reading skills in young children through clinical trials involving 200 pupils.
Prelude Early Learning has secured a $2 million Phase II grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, part of the National Institutes of Health, to expand work on its early literacy platform, according to Silicon Florist. The Portland company, which previously operated under the name Finnegan the Dragon, said the award will support a clinical trial involving about 200 children in 12 classrooms.
Prelude’s approach is built around what it calls music-to-literacy learning. On its website, the company says its flagship programme blends speech-to-print instruction, music, play and voice-powered technology to help young children build the language and pre-reading skills that underpin later reading success. The system is designed for preschoolers and children in family child care settings, as well as educators and families, with classroom lessons linked to interactive digital practice at home.
Emily Cadiz, the company’s founder and chief executive, said early literacy starts well before children recognise letters. “It starts with sounds. Then words. Then conversations. And it grows every time a child gets to use its voice,” Cadiz said. Prelude’s website says its team includes specialists in early childhood reading, special education, speech and language, and English language learning, alongside an advisory board with experience in education and business.
The grant comes a year after Prelude launched in September 2025, when the company said its blended learning model had shown up to 250% growth in pre-reading skills over eight weeks of classroom use. NIH’s small business programs are designed to help U.S. companies advance research with commercial potential, and agency guidance says Phase II awards are generally for up to two years and can reach $2 million. For Prelude, the funding could help move the platform from promising classroom use toward broader validation in a larger trial.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
